Market and company headlines
In October 2026, CG Oncology appointed Isabel Kalofonos as Chief Commercial Officer, tasking her with leading commercial strategy as the company prepares for the potential launch of its bladder cancer therapy cretostimogene grenadenorepvec. Her track record in building commercial organizations and introducing new oncology and rare disease medicines adds experienced leadership at a critical pre-launch phase for CG Oncology. Next, we’ll examine how adding an experienced commercial leader could...
Yahoo·22:10·13 Days AgoCGON▲+2.2%
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms. Kalofonos will lead the Company's commercial strategy and execution as CG Oncology advances toward the potential launch of cretostimogene grenadenorepvec and continues to establish itself as a leader in bladder cancer. "Isabel’s
Yahoo·08:00CGON▲+2.2%
The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on the SBIO ETF.
SeekingAlpha·10:17
CG Oncology, Inc. (CGON) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDTCompany ParticipantsArthur Kuan - President,...
SeekingAlpha·16:01CGON▲+2.2%
CGON, YPF, and IE are three of the most popular stocks amongst call traders
Yahoo·11:35CGON▲+2.2%
